Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancerDavid Miles, Giulia Bianchi, Kunwei Shen et al.|Annals of Oncology|2021Cited by 724
Comprehensive analysis of prognostic immune‐related genes in the tumor microenvironment of cutaneous melanomaSheng Yang, Geyu Liang, Tong Liu et al.|Journal of Cellular Physiology|2019Cited by 111
Organo-Se BTSAs-enabled performance: From racemic and asymmetric synthesis to click chemistry applicationZhi Zhou, Wei Yi, Yuang Gu et al.|Chem|2023Cited by 37
Efficacy of Crizotinib for Advanced ALK-Rearranged Non-Small-Cell Lung Cancer Patients with Brain Metastasis: A Multicenter, Retrospective Study in ChinaPuyuan Xing, Junling Li, Shouzheng Wang et al.|Targeted Oncology|2019Cited by 14
Influence of target dose heterogeneity on dose sparing of normal tissue in peripheral lung tumor stereotactic body radiation therapyZhigong Wei, Jianghong Xiao, Xingchen Peng et al.|Radiation Oncology|2021Cited by 12